Fig. 6: Knockout JAK2 and SRC reduced GC cells' sensitivity to vortioxetine hydrobromide. | Oncogenesis

Fig. 6: Knockout JAK2 and SRC reduced GC cells' sensitivity to vortioxetine hydrobromide.

From: Vortioxetine hydrobromide inhibits the growth of gastric cancer cells in vivo and in vitro by targeting JAK2 and SRC

Fig. 6

A CRISPR/Cas9 system was used to knockout both JAK2 and SRC in HGC27 and AGS cells. Knockout efficiency in GC cells were assessed by Western blotting. B Cell viability after both JAK2 and SRC knockout was assessed by MTT assay. C Colony numbers of JAK2 and SRC knockout cells were measured by colony formation assay. D The protein levels of p-STAT3 Y705 and STAT3 in JAK2 and SRC double knockout cells by Western blotting. E The protein levels of p-STAT3 Y705 and STAT3 in sgControl, sgJAK2, sgSRC and sgJAK2 + sgSRC cells by Western blotting. F The inhibitory effect of vortioxetine hydrobromide on JAK2 and SRC knockout cells was detected by proliferation assay after 96 h. Cell viability was evaluated by MTT assay and normalized to that of the sgcontrol. G JAK2 and SRC knockout cells were plated into 6-well plates and treated with 4 μM vortioxetine hydrobromide for 10 days, followed by crystal violet staining to monitor colony formation. Mean ± S.D. (n = 3) (*p < 0.05, **p < 0.01, ***p < 0.001).

Back to article page